# ADI-270

Source: https://onco.cc/drugs/adi-270/  
OnCo record `adi-270` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ADI-270 is an experimental CAR-T cell therapy from Adicet Therapeutics in phase 2 trials for renal cell carcinoma, aimed at CD70.

## Summary

ADI-270 is a CAR-T cell therapy developed by Adicet Therapeutics. Its target is CD70 (the sponsor names CD70). The sponsor states: An armoured, allogeneic 'off-the-shelf' CAR gamma-delta (CAR-γδ) T-cell therapy directed against CD70-expressing cells, with reported CAR-directed and CAR-independent anti-tumour activity against solid and haematologic malignancies. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in renal cell carcinoma. The largest, NCT06480565, plans to enrol 60 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: An armoured, allogeneic 'off-the-shelf' CAR gamma-delta (CAR-γδ) T-cell therapy directed against CD70-expressing cells, with reported CAR-directed and CAR-independent anti-tumour activity against solid and haematologic malignancies.

## Sources

- ClinicalTrials.gov: trials of ADI-270: https://clinicaltrials.gov/search?intr=ADI-270
- Sponsor pipeline page: https://adicetbio.com/pipeline

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- targets: [CD70](https://onco.cc/targets/cd70/)
- companies: [Adicet Bio](https://onco.cc/companies/adicet-bio/)
- trials: [A Phase 1/2 Trial of ADI-270 in ccRCC](https://onco.cc/trials/nct06480565/)

---
JSON: https://onco.cc/api/v1/entities/adi-270.json